Results 21 to 30 of about 681,792 (231)

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. [PDF]

Clin Cancer Res, 2020
International audienceAbstract Precision oncology relies on the identification of molecular alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors.
Facchinetti F, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, Friboulet L.   +6 more
europepmc   +2 more sources

Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment

Biomedicines, 2023
In carcinogenesis of the gastrointestinal (GI) tract, the deregulation of fibroblast growth factor receptor (FGFR) signaling plays a critical role.
Margherita Ratti, Elena Orlandi, Jens Claus Hahne, Stefano Vecchia, Chiara Citterio, Elisa Anselmi, Ilaria Toscani, Michele Ghidini   +7 more
doaj   +1 more source

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas [PDF]

Nature Communications
Oncogenic alterations in fibroblast growth factor receptor (FGFR)-family proteins occur across cancers, including pediatric gliomas. Our genomic analysis of 11,635 gliomas across ages finds that 5.3% of all gliomas harbor FGFR alterations, with an ...
April A. Apfelbaum, Eric Morin, Dominik Sturm, Georges Ayoub, Jeromy DiGiacomo, Sher Bahadur, Bhavyaa Chandarana, Phoebe C. Power, Margaret M. Cusick, Dana Novikov, Prem Prabhakar, Robert E. Jones, Jayne Vogelzang, Connor C. Bossi, Seth Malinowski, Lewis M. Woodward, Tania A. Jones, John Jeang, Sarah W. Lamson, Jared Collins, Kelly Y. Cai, Jacquelyn S. Jones, Sehee Oh, Hyesung Jeon, Jinhua Wang, Amy Cameron, Patrick Rechter, Angela De Leon, Karthikeyan Murugesan, Meagan Montesion, Lee A. Albacker, Shakti H. Ramkissoon, Cornelis M. van Tilburg, Emily C. Hardin, Philipp Sievers, Felix Sahm, Kee Kiat Yeo, Tom Rosenberg, Susan N. Chi, Karen D. Wright, Steven Hébert, Sydney Peck, Alberto Picca, Valérie Larouche, Samuele Renzi, Sara J. Buhrlage, Tejus A. Bale, Amy A. Smith, Mehdi Touat, Nada Jabado, Eric S. Fischer, Michael J. Eck, Lissa Baird, Olaf Witt, Claudia L. Kleinman, Quang-De Nguyen, Denise Sheer, Sanda Alexandrescu, David T. W. Jones, Keith L. Ligon, Pratiti Bandopadhayay   +60 more
doaj   +2 more sources

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment

Molecular Cancer, 2023
Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer
Ruiwen Ruan, Li Li, Xuan Li, Chunye Huang, Zhanmin Zhang, Hongguang Zhong, Shaocheng Zeng, Qianqian Shi, Yang Xia, Qinru Zeng, Qin Wen, Jingyi Chen, Xiaofeng Dai, Jianping Xiong, Xiaojun Xiang, Wan Lei, Jun Deng   +16 more
doaj   +1 more source

Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +2 more sources

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma

International Journal of Retina and Vitreous, 2021
Background Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous
Oleg Alekseev, Effy Ojuok, Scott Cousins
doaj   +1 more source

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

npj Precision Oncology, 2021
Various genetic alterations of the fibroblast growth factor receptor (FGFR) family have been detected across a wide range of cancers. However, inhibition of FGFR signaling by kinase inhibitors demonstrated limited clinical effectiveness.
Ikuko Takeda Nakamura, Shinji Kohsaka, Masachika Ikegami, Hiroshi Ikeuchi, Toshihide Ueno, Kunhua Li, Tyler S. Beyett, Takafumi Koyama, Toshio Shimizu, Noboru Yamamoto, Fumiyuki Takahashi, Kazuhisa Takahashi, Michael J. Eck, Hiroyuki Mano   +13 more
doaj   +1 more source

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

Frontiers in Chemistry, 2022
Targeted therapy is a groundbreaking innovation for cancer treatment. Among the receptor tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial attention as promising therapeutic targets due to their fundamental biological ...
Jia Zheng, Wei Zhang, Linfeng Li, Yi He, Yue Wei, Yongjun Dang, Shenyou Nie, Zufeng Guo   +7 more
doaj   +1 more source

Second-Generation FGFR Inhibitors for the Treatment of Cancers Harboring Mutated FGFRs. [PDF]

ACS Med Chem Lett, 2019
Abdel-Magid AF.
europepmc   +4 more sources

Fibroblast growth factor receptor fusions in cancer: opportunities and challenges

Journal of Experimental & Clinical Cancer Research, 2021
Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric FGFR fusion proteins, which often cause ...
Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li, Guang Liang   +6 more
doaj   +1 more source